熱門資訊> 正文
中国批准葛兰素史克的Teggy Ellipta用于成人哮喘治疗
2026-01-23 18:51
- GSK (GSK) said on Friday that China’s National Medical Products Administration approved a new indication for Trelegy Ellipta to treat adults with asthma, expanding its approved use beyond chronic obstructive pulmonary disease.
- The approval means that FF/UMEC/VI is the first and only single-inhaler triple therapy approved for the maintenance treatment of both respiratory conditions in the country.
- Approval was based on GSK’s CAPTAIN study, which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI.
- Source: Press release
More on GSK
- GSK plc (GSK) RAPT Therapeutics, Inc. - M&A Call - Slideshow
- RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
- GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake
- RFK Jr. has reportedly removed four members of vaccine injury panel
推薦文章
美股機會日報 | 美國1月「小非農」不及預期！禮來績后一度大漲10%，財報強勁超預期
華盛早報 | 闢謠！税收傳聞不實；「AI搶飯碗」引拋售潮！納指跌近1.5%；黃金、白銀暴力反彈，華爾街堅定看多
全面甩賣軟件股！美股爆發AI恐慌，Anthropic掀起SaaS拋售潮
財報速遞 | 超微電腦盤后一度漲逾10%！強勁業績展望預示AI需求增長
美股機會日報 | 貴金屬「大逆轉」！金銀價再度大漲，機構建議市場回穩再進場；閃迪盤前續漲4%，年內已累漲180%
金銀暴跌后「暴力」反彈！華爾街堅定看多：邏輯未破，黃金牛市仍未結束（附相關標的）
搶跑1.5萬億美元造富神話！如何在IPO前投資SpaceX？最全攻略來了
新股申購 | 「全球鋰電設備龍頭」先導智能今起招股！引入歐萬達基金等基石投資者
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
